- Home
- TNON vs BCDA Comparison
TNON vs BCDA Comparison
Compare TNON & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- BCDA
- Stock Information
- Founded
- TNON 2012
- BCDA N/A
- Country
- TNON United States
- BCDA United States
- Employees
- TNON N/A
- BCDA N/A
- Industry
- TNON Medical Specialities
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- BCDA Health Care
- Exchange
- TNON Nasdaq
- BCDA Nasdaq
- Market Cap
- TNON 10.6M
- BCDA 10.1M
- IPO Year
- TNON 2022
- BCDA N/A
- Fundamental
- Price
- TNON $1.38
- BCDA $1.68
- Analyst Decision
- TNON Strong Buy
- BCDA Strong Buy
- Analyst Count
- TNON 3
- BCDA 1
- Target Price
- TNON $11.67
- BCDA $25.00
- AVG Volume (30 Days)
- TNON 13.4M
- BCDA 634.2K
- Earning Date
- TNON 08-13-2025
- BCDA 08-11-2025
- Dividend Yield
- TNON N/A
- BCDA N/A
- EPS Growth
- TNON N/A
- BCDA N/A
- EPS
- TNON N/A
- BCDA N/A
- Revenue
- TNON $3,284,000.00
- BCDA N/A
- Revenue This Year
- TNON $39.03
- BCDA N/A
- Revenue Next Year
- TNON $66.24
- BCDA N/A
- P/E Ratio
- TNON N/A
- BCDA N/A
- Revenue Growth
- TNON 2.18
- BCDA N/A
- 52 Week Low
- TNON $0.85
- BCDA $1.63
- 52 Week High
- TNON $15.79
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- TNON 65.80
- BCDA 30.84
- Support Level
- TNON $1.30
- BCDA $1.65
- Resistance Level
- TNON $1.63
- BCDA $2.42
- Average True Range (ATR)
- TNON 0.19
- BCDA 0.13
- MACD
- TNON 0.03
- BCDA -0.06
- Stochastic Oscillator
- TNON 27.15
- BCDA 3.90
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).